Conviction
1 → 3
Conviction●●●○○3 of 5
Research target$47.59Snapshot target
Thesis statusINTACTLast reviewed 7/8/26
Market cap$4.76BSnapshot value
Research history
See all TXG changes ↗What changed
Target
— → $47.59
Thesis status
NEEDS_MORE_DATA → INTACT
Last reviewed
Not reviewed → 7/8/26
Target
— → $47.59
Single-cell + spatial biology platform leader. 10x Chromium is the dominant single-cell platform; Visium/Xenium/Atera for spatial. 15% CAGR spatial biology market driven by oncology.
Atera platform launch (Q1 2026) expanding spatial capabilities; Roche Axelios single-cell/spatial partnership; rising cancer burden (35M+ new cases projected by 2050) driving spatial adoption.
Pre-revenue trajectory — unprofitable, narrative-driven; FFPE compatibility and cost remain adoption limiters; competitive pressure from Bruker/Vizgen/Akoya; single-cell market maturation.
needs X/Reddit sentiment sweep
Snapshot · 7/8/26🟢 Lean-Bull · ins-$3.4M · 13F 15+/9- · short↓0.22
Snapshot · 7/8/26